Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kiora Pharmaceuticals, Inc. (KPRX)
USD2.48
+0.00 (+0.00%)
US NASDAQ Healthcare Biotechnology
Address
1371 East 2100 South 84105
Encinitas, UT, US
Encinitas, UT, US
CEO
Brian Strem
Website
kiorapharma.com
IPO
2015-02-13
CIK 1372514 ISIN US49721T5074
Description
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.48
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
497.6K
Beta
-0.38
Float Shares
3.71M
Free Float %
94.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.24% | -2.79% | -1.21% | +17.31% | +5.63% | +23.86% | -23.51% | -88.93% | -99.83% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
2.48
DCF (Unlevered)
2.55
+2.9%
DCF (Levered)
2.03
-18.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-10.59
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-403.5% Q1'26: -11.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -2,295.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.5% ★ Q1'26: -1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.04× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
669.3K
est: 604.5K (+10.7%)
|
407.5K
est: 408.0K (-0.1%)
|
1.65M
est: 1.79M (-7.5%)
|
2.69M
est: 2.69M (+0.0%)
|
12.1K
est: 33.3K (-63.8%)
|
—
est: 16.02M (-100.0%)
|
16.00M
est: 16.76M (-4.5%)
|
—
est: 1.50M (-100.0%)
|
1.50M
1.50M – 1.50M
+0.0% YoY
|
28.78M
28.78M – 28.78M
+1,818.9% YoY
|
22.78M
22.78M – 22.78M
-20.9% YoY
|
56.53M
56.53M – 56.53M
+148.2% YoY
|
167.77M
167.77M – 167.77M
+196.8% YoY
|
| EBITDA |
-13.34M
est: 284.9K (-4,782.1%)
|
-14.54M
est: 192.3K (-7,661.9%)
|
-10.69M
est: 842.0K (-1,369.1%)
|
-6.79M
est: 1.27M (-636.2%)
|
-7.47M
est: 15.7K (-47,667.9%)
|
-12.36M
est: 13.96M (-188.6%)
|
5.70M
est: 14.60M (-61.0%)
|
-9.43M
est: 1.31M (-821.9%)
|
1.31M
1.31M – 1.31M
+0.0% YoY
|
25.08M
25.08M – 25.08M
+1,818.9% YoY
|
19.84M
19.84M – 19.84M
-20.9% YoY
|
49.25M
49.25M – 49.25M
+148.2% YoY
|
146.17M
146.17M – 146.17M
+196.8% YoY
|
| EBIT |
-13.34M
est: 284.7K (-4,786.3%)
|
-14.56M
est: 192.2K (-7,675.8%)
|
-10.72M
est: 841.6K (-1,374.3%)
|
-7.00M
est: 1.27M (-653.4%)
|
-7.51M
est: 15.7K (-47,904.8%)
|
-12.41M
est: 13.95M (-189.0%)
|
5.68M
est: 14.60M (-61.1%)
|
-9.46M
est: 1.31M (-824.0%)
|
1.31M
1.31M – 1.31M
+0.0% YoY
|
25.07M
25.07M – 25.07M
+1,818.9% YoY
|
19.84M
19.84M – 19.84M
-20.9% YoY
|
49.24M
49.24M – 49.24M
+148.2% YoY
|
146.13M
146.13M – 146.13M
+196.8% YoY
|
| Net Income |
-13.34M
est: -33.86B (+100.0%)
|
-13.22M
est: -22.72B (+99.9%)
|
-10.81M
est: -6.79B (+99.8%)
|
-7.10M
est: -3.10B (+99.8%)
|
-6.86M
est: -3.00B (+99.8%)
|
-12.51M
est: 5.08M (-346.5%)
|
3.59M
est: 3.55M (+1.3%)
|
-10.84M
est: -7.02M (-54.4%)
|
-11.86M
-11.86M – -11.86M
-69.0% YoY
|
-4.64M
-4.64M – -4.64M
+60.9% YoY
|
-5.21M
-5.21M – -5.21M
-12.4% YoY
|
3.82M
3.82M – 3.82M
+173.2% YoY
|
20.64M
20.64M – 20.64M
+440.9% YoY
|
| SGA |
5.59M
est: 42.96M (-87.0%)
|
4.64M
est: 29.00M (-84.0%)
|
4.44M
est: 126.98M (-96.5%)
|
4.41M
est: 190.89M (-97.7%)
|
4.24M
est: 2.37M (+79.2%)
|
4.66M
est: 13.93M (-66.5%)
|
5.54M
est: 14.57M (-62.0%)
|
5.75M
est: 1.30M (+340.6%)
|
1.30M
1.30M – 1.30M
+0.0% YoY
|
25.02M
25.02M – 25.02M
+1,818.9% YoY
|
19.80M
19.80M – 19.80M
-20.9% YoY
|
49.14M
49.14M – 49.14M
+148.2% YoY
|
145.84M
145.84M – 145.84M
+196.8% YoY
|
| EPS |
-906.30
est: -8,208.00 (+89.0%)
|
-556.17
est: -5,508.00 (+89.9%)
|
-182.81
est: -1,647.00 (+88.9%)
|
-89.24
est: -752.40 (+88.1%)
|
-70.50
est: -727.20 (+90.3%)
|
-24.25
est: 1.24 (-2,060.5%)
|
0.93
est: 0.87 (+7.5%)
|
-2.60
est: -1.71 (-52.0%)
|
-2.89
-2.89 – -2.89
-69.0% YoY
|
-1.13
-1.13 – -1.13
+60.9% YoY
|
-1.27
-1.27 – -1.27
-12.4% YoY
|
0.93
0.93 – 0.93
+173.2% YoY
|
5.03
5.03 – 5.03
+440.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.42M
OE per share TTM
-2.53
Owner's Yield
-101.86%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
6.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
41
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gilad Aharon | 4.18M | 9.90% | — | 4.18M | — | 4.18M | IN | ONTARIO, CANADA | 2024-05-29 | ↗ |
| 2 | Rosalind Master Fund L.P. | 4.18M | 9.90% | — | 4.18M | — | 4.18M | PN | ONTARIO, CANADA | 2024-05-29 | ↗ |
| 3 | Steven Salamon | 4.18M | 9.90% | — | 4.18M | — | — | IN | ONTARIO, CANADA | 2024-05-29 | ↗ |
| 4 | Daniel B. Asher | 3.47M | 9.99% | — | 3.47M | — | 3.47M | HC, IN | United States of America | 2022-08-01 | ↗ |
| 5 | Intracoastal Capital LLC | 3.47M | 9.99% | — | 3.47M | — | 3.47M | OO | United States of America | 2022-08-01 | ↗ |
| 6 | Mitchell P. Kopin | 3.47M | 9.99% | — | 3.47M | — | 3.47M | HC, IN | United States of America | 2022-08-01 | ↗ |
| 7 | Alex Noah Investors, Inc. | 3.28M | 9.99% | — | 3.28M | — | 3.28M | CO | Illinois | 2022-07-28 | ↗ |
| 8 | Jonathan I. Cope | 3.28M | 9.99% | — | 3.28M | — | 3.28M | IN | Illinois | 2022-07-28 | ↗ |
| 9 | Joshua B. Scheinfeld | 3.28M | 9.99% | — | 3.28M | — | 3.28M | IN | Illinois | 2022-07-28 | ↗ |
| 10 | Lincoln Park Capital Fund, LLC | 3.28M | 9.99% | — | 3.28M | — | 3.28M | OO | Illinois | 2022-07-28 | ↗ |
| 11 | Lincoln Park Capital, LLC | 3.28M | 9.99% | — | 3.28M | — | 3.28M | OO | Illinois | 2022-07-28 | ↗ |
| 12 | Rockledge Capital Corporation | 3.28M | 9.99% | — | 3.28M | — | 3.28M | CO | Illinois | 2022-07-28 | ↗ |
| 13 | Jon M. Plexico | 2.41M | 11.00% | — | 2.41M | — | — | HC, IN | California | 2024-02-09 | ↗ |
| 14 | Stonepine Capital Management, LLC | 2.41M | 11.00% | — | 2.41M | — | — | IA, OO | California | 2024-02-09 | ↗ |
| 15 | Stonepine Capital, L.P. | 2.41M | 11.00% | — | 2.41M | — | — | PN | California | 2024-02-09 | ↗ |
| 16 | Timothy P. Lynch | 2.41M | 11.00% | — | 2.41M | — | — | HC, IN | California | 2024-02-09 | ↗ |
| 17 | 27-4413262 | 2.30M | 9.90% | 2.30M | — | 2.30M | — | OO | Maryland | 2024-02-07 | ↗ |
| 18 | Identification Nos. of above persons (. | 2.30M | 9.90% | 2.30M | — | 2.30M | — | IN | States | 2024-02-07 | ↗ |
| 19 | Empery Asset Management, LP | 534.3K | 4.05% | — | 534.3K | — | — | PN | Delaware | 2022-01-24 | ↗ |
| 20 | Martin D. Hoe | 534.3K | 4.05% | — | 534.3K | — | — | IN | Delaware | 2022-01-24 | ↗ |
| 21 | Ryan M. Lane | 534.3K | 4.05% | — | 534.3K | — | — | IN | Delaware | 2022-01-24 | ↗ |
| 22 | Jeff Easton | 345.5K | 9.90% | 345.5K | — | 345.5K | — | IN | Delaware | 2023-06-13 | ↗ |
| 23 | Lind Global Fund II LP | 345.5K | 9.90% | 345.5K | — | 345.5K | — | PN | Delaware | 2023-06-13 | ↗ |
| 24 | Lind Global Partners II LLC | 345.5K | 9.90% | 345.5K | — | 345.5K | — | OO | Delaware | 2023-06-13 | ↗ |
| 25 | ADAR1 Capital Management GP, LLC | 315.1K | 9.99% | — | 315.1K | — | 315.1K | OO | Texas | 2024-11-14 | ↗ |
| 26 | ADAR1 Capital Management, LLC | 310.8K | 9.99% | — | 310.8K | — | 310.8K | OO | Texas | 2024-11-14 | ↗ |
| 27 | Daniel Schneeberger | 310.8K | 9.99% | — | 310.8K | — | 310.8K | IN | Texas | 2024-11-14 | ↗ |
| 28 | Bigger Capital Fund GP, LLC | 289.5K | 2.20% | — | — | — | 289.5K | OO | Delaware | 2022-01-27 | ↗ |
| 29 | Bigger Capital Fund, LP | 289.5K | 2.20% | — | — | — | 289.5K | PN | Delaware | 2022-01-27 | ↗ |
| 30 | Alyeska Fund GP, LLC | 256.4K | 8.40% | — | 256.4K | — | — | OO | Delaware | 2024-11-14 | ↗ |
| 31 | Alyeska Investment Group, L.P. | 256.4K | 8.40% | — | 256.4K | — | — | IA | Delaware | 2024-11-14 | ↗ |
| 32 | Anand Parekh | 256.4K | 8.40% | — | 256.4K | — | — | IN | Delaware | 2024-11-14 | ↗ |
| 33 | GOLDMAN SACHS & CO. LLC | 180.8K | 6.10% | — | — | 13.00 | 180.8K | BD, IA, OO | — | 2024-11-12 | ↗ |
| 34 | THE GOLDMAN SACHS GROUP, INC. | 180.8K | 6.10% | — | — | 13.00 | 180.8K | HC, CO | — | 2024-11-12 | ↗ |
| 35 | Michael Bigger | 1.0K | 3.30% | — | — | — | 1.0K | IN | Delaware | 2022-01-27 | ↗ |
| 36 | District 2 Capital Fund LP | 1.0K | 1.10% | — | — | — | 1.0K | PN | Delaware | 2022-01-27 | ↗ |
| 37 | District 2 Capital LP | 1.0K | 1.10% | — | — | — | 1.0K | PN | Delaware | 2022-01-27 | ↗ |
| 38 | District 2 GP LLC | 1.0K | 1.10% | — | — | — | 1.0K | OO | Delaware | 2022-01-27 | ↗ |
| 39 | District 2 Holdings LLC | 1.0K | 1.10% | — | — | — | 1.0K | OO | Delaware | 2022-01-27 | ↗ |
| 40 | Lind Global Macro Fund, LP | — | 0.00% | — | — | — | — | PN | Delaware | 2023-02-13 | ↗ |
| 41 | Lind Global Partners LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2023-02-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 3 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - US Core Equity 1 ETF DCOR | 0.00% | 4.0K | 0.14% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 52.0K | 0.05% |
| 3 | Dimensional - US Core Equity 2 ETF DFAC | 0.00% | 9.0K | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
3.8K
Cash buys
—
Cash sales
—
Net activity
-3,764
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Tosca Melissa | Officer | F-InKind | D | Common Stock | 929 | 1.95 | 1.8K | 26,975 | D | ↗ |
| 2026-04-01 | Strem Brian M. | Director / Officer | F-InKind | D | Common Stock | 1,906 | 1.95 | 3.7K | 60,692 | D | ↗ |
| 2026-04-01 | Daniels Eric Joseph | Officer | F-InKind | D | Common Stock | 929 | 1.95 | 1.8K | 31,741 | D | ↗ |
| 2026-03-06 | Tosca Melissa | Officer | A-Award | A | Stock Option (right to buy) | 13,067 | 1.98 | 25.9K | 13,067 | D | ↗ |
| 2026-03-06 | Strem Brian M. | Director / Officer | A-Award | A | Common Stock | 16,733 | 0.00 | — | 62,598 | D | ↗ |
| 2026-03-06 | Daniels Eric Joseph | Officer | A-Award | A | Stock Option (right to buy) | 13,067 | 1.98 | 25.9K | 13,067 | D | ↗ |
| 2026-03-03 | Strem Brian M. | Director / Officer | F-InKind | D | Common Stock | 238 | 2.02 | 480.76 | 45,865 | D | ↗ |
| 2026-03-03 | Daniels Eric Joseph | Officer | F-InKind | D | Common Stock | 238 | 2.02 | 480.76 | 26,137 | D | ↗ |
| 2025-04-01 | Walters-Hoffert Lisa | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.93 | 58.6K | 20,000 | D | ↗ |
| 2025-04-01 | Tosca Melissa | Officer | A-Award | A | Stock Option (right to buy) | 15,543 | 2.93 | 45.5K | 15,543 | D | ↗ |
| 2025-04-01 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 2.93 | 87.9K | 30,000 | D | ↗ |
| 2025-04-01 | Strem Brian M. | Director / Officer | A-Award | A | Stock Option (right to buy) | 31,883 | 2.93 | 93.4K | 31,883 | D | ↗ |
| 2025-04-01 | Stengone Carmine N. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.93 | 58.6K | 20,000 | D | ↗ |
| 2025-04-01 | Shapiro Aron | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.93 | 58.6K | 20,000 | D | ↗ |
| 2025-04-01 | Parsons Erin | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.93 | 58.6K | 20,000 | D | ↗ |
| 2025-04-01 | Hollander David | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.93 | 58.6K | 20,000 | D | ↗ |
| 2025-04-01 | Daniels Eric Joseph | Officer | A-Award | A | Stock Option (right to buy) | 15,543 | 2.93 | 45.5K | 15,543 | D | ↗ |
| 2024-09-11 | Stengone Carmine N. | Director | P-Purchase | A | Common Stock | 1,250 | 3.68 | 4.6K | 1,250 | — | ↗ |
| 2024-09-10 | Shapiro Aron | Director | P-Purchase | A | Common Stock | 3,000 | 3.60 | 10.8K | 3,000 | — | ↗ |
| 2024-08-19 | Walters-Hoffert Lisa | Director | P-Purchase | A | Common Stock | 1,250 | 3.86 | 4.8K | 1,250 | — | ↗ |
| 2024-08-19 | TYLE PRAVEEN | Director | P-Purchase | A | Common Stock | 5,000 | 3.96 | 19.8K | 5,014 | — | ↗ |
| 2024-08-14 | Tosca Melissa | Officer | P-Purchase | A | Common Stock | 2,000 | 3.21 | 6.4K | 13,599 | — | ↗ |
| 2024-07-01 | Walters-Hoffert Lisa | Director | A-Award | A | Stock Option (right to buy) | 1,778 | 4.35 | 7.7K | 1,778 | — | ↗ |
| 2024-07-01 | Tosca Melissa | Officer | A-Award | A | Common Stock | 7,620 | 0.00 | — | 11,599 | — | ↗ |
| 2024-07-01 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (right to buy) | 1,778 | 4.35 | 7.7K | 1,778 | — | ↗ |
| 2024-07-01 | Strem Brian M. | Director / Officer | A-Award | A | Common Stock | 15,629 | 0.00 | — | 30,160 | — | ↗ |
| 2024-07-01 | Stengone Carmine N. | Director | A-Award | A | Stock Option (right to buy) | 1,778 | 4.35 | 7.7K | 1,778 | — | ↗ |
| 2024-07-01 | Shapiro Aron | Director | A-Award | A | Stock Option (right to buy) | 1,778 | 4.35 | 7.7K | 1,778 | — | ↗ |
| 2024-07-01 | Parsons Erin | Director | A-Award | A | Stock Option (right to buy) | 1,778 | 4.35 | 7.7K | 1,778 | — | ↗ |
| 2024-07-01 | Hollander David | Director | A-Award | A | Stock Option (right to buy) | 1,778 | 4.35 | 7.7K | 1,778 | — | ↗ |
| 2024-07-01 | Daniels Eric Joseph | Officer | A-Award | A | Stock Option (right to buy) | 14,710 | 4.35 | 64.0K | 14,710 | — | ↗ |
| 2024-06-14 | Tosca Melissa | Officer | P-Purchase | A | Common Stock | 100 | 5.25 | 525.00 | 3,979 | — | ↗ |
| 2024-06-14 | Daniels Eric Joseph | Officer | P-Purchase | A | Common Stock | 1,431 | 5.29 | 7.6K | 11,222 | — | ↗ |
| 2024-06-13 | Strem Brian M. | Director / Officer | P-Purchase | A | Common Stock | 3,000 | 5.00 | 15.0K | 14,531 | — | ↗ |
| 2024-06-13 | Parsons Erin | Director | P-Purchase | A | Common Stock | 5,260 | 4.88 | 25.7K | 5,260 | — | ↗ |
| 2023-09-29 | Tosca Melissa | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 34,900 | — | ↗ |
| 2023-09-29 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.57 | 2.8K | 5,000 | — | ↗ |
| 2023-09-29 | Strem Brian M. | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 103,783 | — | ↗ |
| 2023-09-29 | Stengone Carmine N. | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 0.57 | 4.5K | 8,000 | — | ↗ |
| 2023-09-29 | Shapiro Aron | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.57 | 2.8K | 5,000 | — | ↗ |
| 2023-09-29 | Parsons Erin | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.57 | 2.8K | 5,000 | — | ↗ |
| 2023-09-29 | Hollander David | Director | A-Award | A | Stock Option (right to buy) | 0 | 0.57 | — | 5,000 | — | ↗ |
| 2023-09-29 | Gayron Kenneth L | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.57 | 2.8K | 5,000 | — | ↗ |
| 2023-09-29 | Daniels Eric Joseph | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 0.57 | 71.0K | 125,000 | — | ↗ |
| 2023-08-01 | Stengone Carmine N. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-03 | Tosca Melissa | Officer | A-Award | A | Stock Option (right to buy) | 1,600 | 3.83 | 6.1K | 1,600 | — | ↗ |
| 2023-03-03 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 3.83 | 30.6K | 8,000 | — | ↗ |
| 2023-03-03 | Strem Brian M. | Director / Officer | A-Award | A | Common Stock | 15,600 | 3.83 | 59.7K | 28,783 | — | ↗ |
| 2023-03-03 | Shapiro Aron | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 3.83 | 30.6K | 8,000 | — | ↗ |
| 2023-03-03 | Parsons Erin | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 3.83 | 30.6K | 8,000 | — | ↗ |
| 2023-03-03 | Hollander David | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 3.83 | 30.6K | 8,000 | — | ↗ |
| 2023-03-03 | Gayron Kenneth L | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 3.83 | 30.6K | 8,000 | — | ↗ |
| 2023-03-03 | Daniels Eric Joseph | Officer | A-Award | A | Stock Option (right to buy) | 10,400 | 3.83 | 39.8K | 10,400 | — | ↗ |
| 2023-03-03 | CHANEY PAUL G | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 3.83 | 30.6K | 8,000 | — | ↗ |
| 2022-10-21 | Tosca Melissa | Officer | A-Award | A | Common Stock | 2,500 | 0.00 | — | 2,500 | — | ↗ |
| 2022-10-21 | Strem Brian M. | Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 13,183 | — | ↗ |
| 2022-10-21 | Daniels Eric Joseph | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 10,238 | — | ↗ |
| 2022-09-13 | Tosca Melissa | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-21 | Drexler Susan L. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-10 | Romano Sarah | Officer | F-InKind | D | Common Stock | 108 | 0.69 | 74.52 | 22,746 | — | ↗ |
| 2022-02-01 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.77 | 3.9K | 5,000 | — | ↗ |
| 2022-02-01 | Strem Brian M. | Director / Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 0.77 | 57.8K | 75,000 | — | ↗ |
| 2022-02-01 | Shapiro Aron | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.77 | 3.9K | 5,000 | — | ↗ |
| 2022-02-01 | Romano Sarah | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.77 | 38.5K | 50,000 | — | ↗ |
| 2022-02-01 | Parsons Erin | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.77 | 3.9K | 5,000 | — | ↗ |
| 2022-02-01 | Hollander David | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.77 | 3.9K | 5,000 | — | ↗ |
| 2022-02-01 | Gayron Kenneth L | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.77 | 3.9K | 5,000 | — | ↗ |
| 2022-02-01 | Daniels Eric Joseph | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 0.77 | 19.3K | 25,000 | — | ↗ |
| 2022-02-01 | CHANEY PAUL G | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.77 | 3.9K | 5,000 | — | ↗ |
| 2022-01-31 | Parsons Erin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-05 | Romano Sarah | Officer | F-InKind | D | Common Stock | 114 | 1.08 | 123.12 | 22,854 | — | ↗ |
| 2022-01-05 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 326 | 1.08 | 352.08 | 67,693 | — | ↗ |
| 2021-12-13 | Hollander David | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-07 | Romano Sarah | Officer | F-InKind | D | Common Stock | 91 | 1.30 | 118.30 | 22,968 | — | ↗ |
| 2021-12-07 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 273 | 1.30 | 354.90 | 68,019 | — | ↗ |
| 2021-11-18 | Strem Brian M. | Director / Officer | P-Purchase | A | Common Stock | 17,853 | 1.41 | 25.2K | 27,370 | — | ↗ |
| 2021-11-02 | Romano Sarah | Officer | F-InKind | D | Common Stock | 83 | 1.98 | 164.34 | 23,059 | — | ↗ |
| 2021-11-02 | Mann Brenda | Officer | F-InKind | D | Common Stock | 62 | 1.98 | 122.76 | 15,136 | — | ↗ |
| 2021-11-02 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 250 | 1.98 | 495.00 | 68,292 | — | ↗ |
| 2021-10-21 | Strem Brian M. | Director / Officer | A-Award | A | Common Stock | 9,517 | 0.00 | — | 9,517 | — | ↗ |
| 2021-10-21 | Daniels Eric Joseph | Officer | A-Award | A | Common Stock | 9,520 | 0.00 | — | 9,520 | — | ↗ |
| 2021-10-04 | Romano Sarah | Officer | F-InKind | D | Common Stock | 83 | 2.01 | 166.83 | 23,142 | — | ↗ |
| 2021-10-04 | Mann Brenda | Officer | F-InKind | D | Common Stock | 62 | 2.01 | 124.62 | 15,198 | — | ↗ |
| 2021-10-04 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 249 | 2.01 | 500.49 | 68,542 | — | ↗ |
| 2021-09-02 | Romano Sarah | Officer | F-InKind | D | Common Stock | 84 | 1.81 | 152.04 | 23,225 | — | ↗ |
| 2021-09-02 | Mann Brenda | Officer | F-InKind | D | Common Stock | 61 | 1.81 | 110.41 | 15,260 | — | ↗ |
| 2021-09-02 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 253 | 1.81 | 457.93 | 68,791 | — | ↗ |
| 2021-08-03 | Romano Sarah | Officer | F-InKind | D | Common Stock | 87 | 2.40 | 208.80 | 23,309 | — | ↗ |
| 2021-08-03 | Mann Brenda | Officer | F-InKind | D | Common Stock | 63 | 2.40 | 151.20 | 15,321 | — | ↗ |
| 2021-08-03 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 65 | 2.40 | 156.00 | 15,378 | — | ↗ |
| 2021-08-03 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 261 | 2.40 | 626.40 | 69,044 | — | ↗ |
| 2021-08-02 | ARMISTICE CAPITAL, LLC | 10% Owner | S-Sale | D | Common Stock | 192,775 | 2.40 | 463.0K | 785,000 | — | ↗ |
| 2021-07-30 | ARMISTICE CAPITAL, LLC | 10% Owner | S-Sale | D | Common Stock | 68,188 | 2.69 | 183.6K | 977,775 | — | ↗ |
| 2021-07-29 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 400,000 | 3.00 | 1.20M | 1,045,963 | — | ↗ |
| 2021-07-28 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 375,443 | 3.28 | 1.23M | 1,445,963 | — | ↗ |
| 2021-07-27 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 73,101 | 7.06 | 516.1K | 4,126,000 | — | ↗ |
| 2021-07-26 | Strem Brian M. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-02 | Romano Sarah | Officer | F-InKind | D | Common Stock | 180 | 3.70 | 666.00 | 23,396 | — | ↗ |
| 2021-07-02 | Mann Brenda | Officer | F-InKind | D | Common Stock | 154 | 3.70 | 569.80 | 15,384 | — | ↗ |
| 2021-07-02 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 160 | 3.70 | 592.00 | 15,443 | — | ↗ |
| 2021-07-02 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 877 | 3.70 | 3.2K | 69,305 | — | ↗ |
| 2021-06-04 | Romano Sarah | Officer | F-InKind | D | Common Stock | 180 | 4.19 | 754.20 | 23,576 | — | ↗ |
| 2021-06-04 | Mann Brenda | Officer | F-InKind | D | Common Stock | 155 | 4.19 | 649.45 | 15,538 | — | ↗ |
| 2021-06-04 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 155 | 4.19 | 649.45 | 15,603 | — | ↗ |
| 2021-06-04 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 878 | 4.19 | 3.7K | 70,182 | — | ↗ |
| 2021-05-04 | Romano Sarah | Officer | F-InKind | D | Common Stock | 177 | 4.13 | 731.01 | 23,756 | — | ↗ |
| 2021-05-04 | Mann Brenda | Officer | F-InKind | D | Common Stock | 191 | 4.13 | 788.83 | 15,693 | — | ↗ |
| 2021-05-04 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 158 | 4.13 | 652.54 | 15,758 | — | ↗ |
| 2021-05-04 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 889 | 4.13 | 3.7K | 71,060 | — | ↗ |
| 2021-04-19 | Shapiro Aron | Director | A-Award | A | Stock Option (right to buy) | 4,000 | 4.40 | 17.6K | 4,000 | — | ↗ |
| 2021-04-19 | Gayron Kenneth L | Director | A-Award | A | Stock Option (right to buy) | 4,000 | 4.40 | 17.6K | 4,000 | — | ↗ |
| 2021-04-08 | Romano Sarah | Officer | F-InKind | D | Common Stock | 180 | 4.94 | 889.20 | 23,933 | — | ↗ |
| 2021-04-08 | Mann Brenda | Officer | F-InKind | D | Common Stock | 192 | 4.94 | 948.48 | 15,884 | — | ↗ |
| 2021-04-08 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 194 | 4.94 | 958.36 | 15,916 | — | ↗ |
| 2021-04-08 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 899 | 4.94 | 4.4K | 71,949 | — | ↗ |
| 2021-04-01 | Shapiro Aron | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-01 | Gayron Kenneth L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-03 | Romano Sarah | Officer | F-InKind | D | Common Stock | 218 | 5.46 | 1.2K | 24,113 | — | ↗ |
| 2021-03-03 | Mann Brenda | Officer | F-InKind | D | Common Stock | 192 | 5.46 | 1.0K | 16,076 | — | ↗ |
| 2021-03-03 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 192 | 5.46 | 1.0K | 16,110 | — | ↗ |
| 2021-03-03 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 898 | 5.46 | 4.9K | 72,848 | — | ↗ |
| 2021-02-02 | Romano Sarah | Officer | F-InKind | D | Common Stock | 1,282 | 6.34 | 8.1K | 24,331 | — | ↗ |
| 2021-02-02 | Mann Brenda | Officer | F-InKind | D | Common Stock | 988 | 6.34 | 6.3K | 16,268 | — | ↗ |
| 2021-02-02 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 990 | 6.34 | 6.3K | 16,302 | — | ↗ |
| 2021-02-02 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 3,542 | 6.34 | 22.5K | 73,746 | — | ↗ |
| 2021-02-01 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (right to buy) | 3,333 | 6.46 | 21.5K | 3,333 | — | ↗ |
| 2021-02-01 | Romano Sarah | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 6.46 | 193.8K | 30,000 | — | ↗ |
| 2021-02-01 | Obermayr Franz | Officer | — | D | Common Stock | 0 | 0.00 | — | 101,613 | — | ↗ |
| 2021-02-01 | Mann Brenda | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 6.46 | 64.6K | 10,000 | — | ↗ |
| 2021-02-01 | MANZO MICHAEL P. | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 6.46 | 64.6K | 10,000 | — | ↗ |
| 2021-02-01 | MALFROY-CAMINE BERNARD | Director | A-Award | A | Stock Option (right to buy) | 3,333 | 6.46 | 21.5K | 3,333 | — | ↗ |
| 2021-02-01 | HANCOCK THOMAS | Director | A-Award | A | Stock Option (right to buy) | 3,333 | 6.46 | 21.5K | 3,333 | — | ↗ |
| 2021-02-01 | GOLDBERG MORTON | Director | A-Award | A | Stock Option (right to buy) | 3,333 | 6.46 | 21.5K | 3,333 | — | ↗ |
| 2021-02-01 | FROM STEPHEN | Director / Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 6.46 | 64.6K | 10,000 | — | ↗ |
| 2021-02-01 | CHANEY PAUL G | Director | A-Award | A | Stock Option (right to buy) | 3,333 | 6.46 | 21.5K | 3,333 | — | ↗ |
| 2021-01-06 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 0 | 0.00 | — | 3,346,601 | — | ↗ |
| 2021-01-04 | Romano Sarah | Officer | F-InKind | D | Common Stock | 115 | 4.85 | 557.75 | 25,613 | — | ↗ |
| 2021-01-04 | Mann Brenda | Officer | F-InKind | D | Common Stock | 115 | 4.85 | 557.75 | 17,256 | — | ↗ |
| 2021-01-04 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 115 | 4.85 | 557.75 | 17,292 | — | ↗ |
| 2021-01-04 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 705 | 4.85 | 3.4K | 77,288 | — | ↗ |
| 2020-12-07 | Romano Sarah | Officer | F-InKind | D | Common Stock | 91 | 3.76 | 342.16 | 25,728 | — | ↗ |
| 2020-12-07 | Mann Brenda | Officer | F-InKind | D | Common Stock | 91 | 3.76 | 342.16 | 17,371 | — | ↗ |
| 2020-12-07 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 91 | 3.76 | 342.16 | 17,407 | — | ↗ |
| 2020-12-07 | FROM STEPHEN | Officer | F-InKind | D | Common Stock | 588 | 3.76 | 2.2K | 77,993 | — | ↗ |
| 2020-11-02 | Romano Sarah | Officer | F-InKind | D | Common Stock | 97 | 3.51 | 340.47 | 25,819 | — | ↗ |
| 2020-11-02 | Mann Brenda | Officer | F-InKind | D | Common Stock | 96 | 3.51 | 336.96 | 17,462 | — | ↗ |
| 2020-11-02 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 97 | 3.51 | 340.47 | 17,498 | — | ↗ |
| 2020-11-02 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 623 | 3.51 | 2.2K | 78,581 | — | ↗ |
| 2020-10-02 | Romano Sarah | Officer | F-InKind | D | Common Stock | 98 | 3.88 | 380.24 | 25,916 | — | ↗ |
| 2020-10-02 | Mann Brenda | Officer | F-InKind | D | Common Stock | 98 | 3.88 | 380.24 | 17,558 | — | ↗ |
| 2020-10-02 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 98 | 3.88 | 380.24 | 17,595 | — | ↗ |
| 2020-10-02 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 631 | 3.88 | 2.4K | 79,204 | — | ↗ |
| 2020-09-02 | Romano Sarah | Officer | F-InKind | D | Common Stock | 97 | 3.94 | 382.18 | 26,014 | — | ↗ |
| 2020-09-02 | Mann Brenda | Officer | F-InKind | D | Common Stock | 97 | 3.94 | 382.18 | 17,656 | — | ↗ |
| 2020-09-02 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 97 | 3.94 | 382.18 | 17,693 | — | ↗ |
| 2020-09-02 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 628 | 3.94 | 2.5K | 79,835 | — | ↗ |
| 2020-08-04 | Romano Sarah | Officer | F-InKind | D | Common Stock | 95 | 4.11 | 390.45 | 26,111 | — | ↗ |
| 2020-08-04 | Mann Brenda | Officer | F-InKind | D | Common Stock | 92 | 4.11 | 378.12 | 17,753 | — | ↗ |
| 2020-08-04 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 95 | 4.11 | 390.45 | 17,790 | — | ↗ |
| 2020-08-04 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 615 | 4.11 | 2.5K | 80,463 | — | ↗ |
| 2020-07-02 | Romano Sarah | Officer | F-InKind | D | Common Stock | 97 | 4.82 | 467.54 | 26,206 | — | ↗ |
| 2020-07-02 | Mann Brenda | Officer | F-InKind | D | Common Stock | 94 | 4.82 | 453.08 | 17,845 | — | ↗ |
| 2020-07-02 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 97 | 4.82 | 467.54 | 17,885 | — | ↗ |
| 2020-07-02 | FROM STEPHEN | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 625 | 4.82 | 3.0K | 81,078 | — | ↗ |
| 2020-06-03 | Romano Sarah | Officer | F-InKind | D | Common Stock | 94 | 5.11 | 480.34 | 26,303 | — | ↗ |
| 2020-06-03 | Mann Brenda | Officer | F-InKind | D | Common Stock | 94 | 5.11 | 480.34 | 17,939 | — | ↗ |
| 2020-06-03 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 94 | 5.11 | 480.34 | 17,982 | — | ↗ |
| 2020-06-03 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 627 | 5.11 | 3.2K | 81,703 | — | ↗ |
| 2020-05-05 | Romano Sarah | Officer | F-InKind | D | Common Stock | 93 | 5.10 | 474.30 | 26,397 | — | ↗ |
| 2020-05-05 | Mann Brenda | Officer | F-InKind | D | Common Stock | 113 | 5.10 | 576.30 | 18,033 | — | ↗ |
| 2020-05-05 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 93 | 5.10 | 474.30 | 18,076 | — | ↗ |
| 2020-05-05 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 617 | 5.10 | 3.1K | 82,330 | — | ↗ |
| 2020-04-02 | Romano Sarah | Officer | F-InKind | D | Common Stock | 122 | 4.97 | 606.34 | 26,490 | — | ↗ |
| 2020-04-02 | Mann Brenda | Officer | F-InKind | D | Common Stock | 122 | 4.97 | 606.34 | 18,146 | — | ↗ |
| 2020-04-02 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 122 | 4.97 | 606.34 | 18,169 | — | ↗ |
| 2020-04-02 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 670 | 4.97 | 3.3K | 82,947 | — | ↗ |
| 2020-03-09 | Romano Sarah | Officer | F-InKind | D | Common Stock | 130 | 5.01 | 651.30 | 26,612 | — | ↗ |
| 2020-03-09 | Mann Brenda | Officer | F-InKind | D | Common Stock | 130 | 5.00 | 650.00 | 18,268 | — | ↗ |
| 2020-03-09 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 130 | 5.01 | 651.30 | 18,291 | — | ↗ |
| 2020-03-09 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 712 | 5.00 | 3.6K | 83,617 | — | ↗ |
| 2020-02-14 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (right to buy) | 3,333 | 6.55 | 21.8K | 3,333 | — | ↗ |
| 2020-02-14 | Romano Sarah | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 26,742 | — | ↗ |
| 2020-02-14 | Mann Brenda | Officer | A-Award | A | Common Stock | 7,500 | 0.00 | — | 18,398 | — | ↗ |
| 2020-02-14 | MANZO MICHAEL P. | Officer | A-Award | A | Stock Option (right to buy) | 7,500 | 6.55 | 49.1K | 7,500 | — | ↗ |
| 2020-02-14 | MALFROY-CAMINE BERNARD | Director | A-Award | A | Stock Option (right to buy) | 3,333 | 6.55 | 21.8K | 3,333 | — | ↗ |
| 2020-02-14 | HANCOCK THOMAS | Director | A-Award | A | Stock Option (right to buy) | 3,333 | 6.55 | 21.8K | 3,333 | — | ↗ |
| 2020-02-14 | GOLDBERG MORTON | Director | A-Award | A | Stock Option (right to buy) | 3,333 | 6.55 | 21.8K | 3,333 | — | ↗ |
| 2020-02-14 | FROM STEPHEN | Director / Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 6.55 | 196.5K | 30,000 | — | ↗ |
| 2020-02-14 | CHANEY PAUL G | Director | A-Award | A | Stock Option (right to buy) | 3,333 | 6.55 | 21.8K | 3,333 | — | ↗ |
| 2020-02-10 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 12,000 | 6.04 | 72.5K | 1,815,500 | — | ↗ |
| 2020-02-06 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 11,000 | 6.18 | 68.0K | 1,803,500 | — | ↗ |
| 2020-02-04 | Romano Sarah | Officer | F-InKind | D | Common Stock | 109 | 6.00 | 654.00 | 16,742 | — | ↗ |
| 2020-02-04 | Mann Brenda | Officer | F-InKind | D | Common Stock | 109 | 6.00 | 654.00 | 10,898 | — | ↗ |
| 2020-02-04 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 109 | 6.00 | 654.00 | 10,921 | — | ↗ |
| 2020-02-04 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 584 | 6.00 | 3.5K | 64,329 | — | ↗ |
| 2020-01-10 | Maher Illya Keith | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-01-03 | Romano Sarah | Officer | F-InKind | D | Common Stock | 119 | 9.52 | 1.1K | 16,851 | — | ↗ |
| 2020-01-03 | Mann Brenda | Officer | F-InKind | D | Common Stock | 119 | 9.52 | 1.1K | 11,007 | — | ↗ |
| 2020-01-03 | MANZO MICHAEL P. | Officer | F-InKind | D | Common Stock | 119 | 9.52 | 1.1K | 11,030 | — | ↗ |
| 2020-01-03 | FROM STEPHEN | Director / Officer | F-InKind | D | Common Stock | 730 | 9.52 | 6.9K | 64,913 | — | ↗ |
Executive team
Top executives
Shares Outstanding
3.95M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Brian M. Strem, Ph.D President and Chief Executive Officer | 489.6K | 268.8K | 68.0K | 125.7K | — | 2.9K | 954.9K | 20.28% | ↗ |
| 2 | 2024 | Eric J. Daniels, MD, MBA Chief Development Officer | 388.2K | 175.8K | 32.0K | 59.1K | — | 18.9K | 674.1K | 13.52% | ↗ |
| 3 | 2024 | Melissa Tosca Chief Financial Officer | 323.6K | 113.3K | 33.1K | 61.3K | — | 2.9K | 534.2K | 17.67% | ↗ |
| 4 | 2023 | Brian M. Strem, Ph.D President and Chief Executive Officer | 416.0K | 170.0K | 102.3K | 114.0K | — | 2.9K | 805.2K | 26.87% | ↗ |
| 5 | 2023 | Eric J. Daniels, MD, MBA Chief Development Officer | 338.6K | 117.6K | 95.2K | 101.1K | — | 17.5K | 670.0K | 29.30% | ↗ |
| 6 | 2023 | Melissa Tosca Chief Financial Officer | 304.5K | 20.0K | 26.2K | 36.7K | — | 2.9K | 390.3K | 16.13% | ↗ |
| 7 | 2023 | Melissa Tosca Executive Vice President of Finance | 304.5K | 20.0K | 26.3K | 36.7K | — | — | 387.5K | 16.26% | ↗ |
| 8 | 2022 | Brian M. Strem, Ph.D President and Chief Executive Officer | 400.0K | 64.9K | 84.8K | 164.5K | — | — | 714.2K | 34.90% | ↗ |
| 9 | 2022 | Eric J. Daniels, MD, MBA Chief Development Officer | 350.5K | 21.0K | 67.8K | 107.6K | — | — | 546.9K | 32.08% | ↗ |
| 10 | 2022 | Stephen From Former Executive Chairman; former President and Chief Executive Officer | 18.2K | — | — | — | — | 363.6K | 381.9K | 0.00% | ↗ |
| 11 | 2022 | Sarah Romano Former Chief Financial Officer | 56.5K | 61.9K | — | 34.1K | — | 18.8K | 171.2K | 19.90% | ↗ |
| 12 | 2022 | Melissa Tosca Executive Vice President of Finance | 85.4K | — | 17.0K | 30.2K | — | — | 132.5K | 35.58% | ↗ |
| 13 | 2021 | Franz Obermayr, Ph.D. Former Acting Chief Executive Officer; former EVP Clinical Development | 288.0K | — | — | 172.5K | — | 121.0K | 581.5K | 29.67% | ↗ |
| 14 | 2021 | Sarah Romano Former Chief Financial Officer | 275.0K | 64.5K | — | 172.7K | — | — | 512.2K | 33.72% | ↗ |
| 15 | 2021 | Stephen From Former Executive Chairman; former President and Chief Executive Officer | 245.3K | 160.0K | — | 57.7K | — | — | 463.0K | 12.47% | ↗ |
| 16 | 2021 | Brian M. Strem, Ph.D President and Chief Executive Officer | 169.2K | — | — | 274.8K | — | — | 444.0K | 61.88% | ↗ |
| 17 | 2021 | Eric J. Daniels, MD, MBA Chief Development Officer | 68.4K | — | — | 87.7K | — | — | 156.1K | 56.19% | ↗ |
| 18 | 2020 | Stephen From Former Executive Chairman; former President and Chief Executive Officer | 400.0K | 160.0K | 129.3K | 193.9K | — | — | 883.2K | 36.59% | ↗ |
| 19 | 2020 | Stephen From Executive Chairman; Former President and Chief Executive Officer | 400.0K | 160.0K | 129.3K | 193.9K | — | — | 883.2K | 36.59% | ↗ |
| 20 | 2020 | Sarah Romano Former Chief Financial Officer | 264.4K | 60.0K | 64.6K | 64.6K | — | — | 453.6K | 28.50% | ↗ |
| 21 | 2020 | Sarah Romano Chief Financial Officer | 264.4K | 60.0K | 64.6K | 64.6K | — | — | 453.6K | 28.50% | ↗ |
| 22 | 2020 | Michael Manzo Vice President of Engineering | 250.0K | 60.0K | 48.5K | 48.5K | — | — | 407.0K | 23.83% | ↗ |
| 23 | 2020 | Franz Obermayr, Ph.D. Former Acting Chief Executive Officer; former EVP Clinical Development | 8.5K | — | — | — | — | — | 8.5K | 0.00% | ↗ |
| 24 | 2019 | Stephen From Executive Chairman; Former President and Chief Executive Officer | 400.0K | 106.6K | — | 94.7K | — | — | 601.3K | 15.75% | ↗ |
| 25 | 2019 | Stephen From President and Chief Executive Officer | 400.0K | 106.6K | — | 94.7K | — | — | 601.3K | 15.75% | ↗ |
| 26 | 2019 | Michael Manzo Vice President of Engineering | 250.0K | 94.2K | — | 23.7K | — | — | 367.9K | 6.44% | ↗ |
| 27 | 2019 | Sarah Romano Chief Financial Officer | 250.0K | 86.0K | — | 23.7K | — | — | 359.7K | 6.58% | ↗ |
| 28 | 2019 | Barbara Wirostko, MD Former Chief Medical Officer | 193.3K | 44.8K | — | 23.7K | — | — | 261.7K | 9.05% | ↗ |
| 29 | 2018 | Stephen From President and Chief Executive Officer | 400.0K | 100.0K | 427.5K | 72.0K | — | — | 999.5K | 49.97% | ↗ |
| 30 | 2018 | Stephen From, President and Chief Executive Officer | 400.0K | 100.0K | 427.5K | 72.0K | — | — | 999.5K | 49.97% | ↗ |
| 31 | 2018 | Barbara Wirostko, MD Former Chief Medical Officer | 280.0K | 42.0K | 99.8K | 12.0K | — | — | 433.8K | 25.76% | ↗ |
| 32 | 2018 | Barbara Wirostko, Chief Medical Officer | 280.0K | 42.0K | 99.8K | 12.0K | — | — | 433.8K | 25.76% | ↗ |
| 33 | 2018 | Michael Manzo, Vice President of Engineering | 250.0K | 65.6K | 99.8K | 12.0K | — | — | 427.4K | 26.15% | ↗ |
| 34 | 2018 | Michael Manzo Vice President of Engineering | 250.0K | 65.6K | 99.8K | 12.0K | — | — | 427.4K | 26.15% | ↗ |
| 35 | 2018 | Sarah Romano Chief Financial Officer | 212.5K | 23.9K | 99.8K | 12.0K | — | — | 348.1K | 32.10% | ↗ |
| 36 | 2017 | Stephen From, President and Chief Executive Officer | 400.0K | 200.0K | 91.2K | 183.8K | — | — | 875.0K | 31.42% | ↗ |
| 37 | 2017 | Barbara Wirostko, Chief Medical Officer | 280.0K | 68.8K | 22.8K | 40.6K | — | — | 412.2K | 15.38% | ↗ |
| 38 | 2017 | Michael Manzo, Vice President of Engineering | 250.0K | 75.0K | — | 55.1K | — | — | 380.1K | 14.50% | ↗ |
| 39 | 2016 | Stephen From, President and Chief Executive Officer | 400.0K | 275.0K | — | 246.9K | — | — | 921.9K | 26.78% | ↗ |
| 40 | 2016 | Michael Manzo, Vice President of Engineering | 250.0K | 105.0K | — | 55.9K | — | — | 410.9K | 13.61% | ↗ |
| 41 | 2016 | Barbara Wirostko, Chief Medical Officer | 213.7K | — | — | 90.0K | — | — | 303.7K | 29.64% | ↗ |
| 42 | 2015 | Stephen From, President and Chief Executive Officer | 323.6K | 130.0K | — | 643.8K | — | — | 1.10M | 58.66% | ↗ |
| 43 | 2015 | Michael Manzo, Vice President of Engineering | 215.6K | — | — | 195.3K | — | — | 410.9K | 47.53% | ↗ |
| 44 | 2014 | Stephen From, President and Chief Executive Officer | 275.1K | 130.0K | — | — | — | 281.5K | 686.6K | 0.00% | ↗ |
| 45 | 2014 | Michael Manzo, Vice President of Engineering | 175.0K | — | — | — | — | — | 175.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brian Strem | President, Chief Executive Officer & Director | 761.2K | — |
| Eric J. Daniels | Chief Development Officer | 582.9K | — |
| Melissa Tosca | Chief Financial Officer | 439.8K | female |
| Stefan Sperl | Executive Vice President of CMC & Operations | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KPRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
